Memphasys Ltd
0.01
AUD
0.00
(0.00%)
ISIN
AU000000MEM5
Return %
Stock
S&P 500
1Y
66.67
14.20
3Y
-45.87
81.12
5Y
-91.14
68.34
Capital Structure
AUD
•
in mil. unless spec.Working Capital
AUD
•
in mil. unless spec.Growth Rates
AUD
•
in mil. unless spec.Semi-annual Revenue
AUD
•
in mil. unless spec.Semi-annual Earnings Per Share
AUD
•
in mil. unless spec.Semi-annual Dividends Per Share
AUD
•
in mil. unless spec.Company Description
- CEO
- R. John Aitken
- Full Time Employees
- 24
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- 30 Richmond Road Sydney NSW Australia 2140
- IPO Date
- Mar 19, 2007
- Website
- memphasys.com
- Similar Companies
- Business
- Memphasys Limited (ASX: MEM) is an Australian-based reproductive biotechnology company that develops and commercializes novel devices, diagnostics, and media for assisted reproductive technology (ART) applications in humans and animals. Founded in 2006 and headquartered at 30 Richmond Road, Homebush West, NSW, the company offers the patented Felix System, an automated electrophoretic device comprising a reusable console and disposable cartridges that rapidly separates high-quality sperm from semen samples using proprietary electrophoresis and size-exclusion membrane technology, excluding contaminants like leukocytes and precursor germ cells; the RoXsta System, a point-of-care diagnostic platform including a Mega Cell High-Throughput Assay for measuring oxidative stress and antioxidant levels in biological fluids such as seminal plasma, blood, and milk; and a pipeline of specialty media products, including long-term ambient temperature storage solutions for human sperm, improved media for sperm isolation, fertilization, and cryopreservation, and advanced selection methods for intracytoplasmic sperm injection (ICSI). Operations span human fertility clinics and veterinary applications, with commercial sales of the Felix System underway in early-access markets including Japan, New Zealand, Canada, India, and the United Arab Emirates; distribution partnerships such as with Vitrolife Japan KK and Panacea Medizintech LLC in the Middle East and North Africa; and ongoing clinical studies in equine, bovine, and dairy sectors via collaborations with the University of Newcastle, EquiBreedUK, and others. In the last year, Memphasys completed a pivotal Phase III clinical trial with Monash IVF in early 2025 demonstrating the Felix System's superiority to density gradient centrifugation and non-inferiority to swim-up methods with zero adverse events, submitted its CE Mark dossier in June 2025 targeting approval within 6-12 months to enable expansion into Europe and CE-equivalent markets, shifted to a direct-sales strategy in low-regulation jurisdictions while maintaining distributor relationships, received initial orders including from a Dubai clinic and pilot cartridge sales in Japan with repeat purchases, secured provisional patent approval for RoXsta from WIPO in November 2024 providing protection to 2044, published landmark validation in the journal Antioxidants in January 2025, and strengthened leadership with appointments including permanent CEO Dr. David Ali in July 2024, Non-Executive Chairperson Dr. Lindley Edwards in November 2024, and Non-Executive Director Marjan Mikel in June 2025.
Company News
Memphasys signs national supply agreement with Monash IVF for Felix sperm selection system
FTSE 100 Live: Stocks called higher as Trump words on Israel help oil retreat
Anthropic confidentially files to go public in the US
Memphasys secures first South-East Asian commercialisation agreement for Felix™
Small Cap Watch: commercial expansion updates drive news flow